• 1
    Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49:S156-165.
  • 2
    Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-188.
  • 3
    Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012;9:156-166.
  • 4
    Watanabe T, Tanaka Y. Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatol Res 2013;43:113-121.
  • 5
    Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57:1-20.
  • 6
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539.
  • 7
    Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007;37:705-712.
  • 8
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
  • 9
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
  • 10
    Buti M, Garcia-Samaniego J, Prieto M, Rodriguez M, Sanchez-Tapias JM, Suarez E, et al. [Consensus document of the Spanish Association for the Study of the Liver on the treatment of hepatitis B infection (2012).] Gastroenterol Hepatol 2012;35:512-528.
  • 11
    Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-934.
  • 12
    Liang RH, Lok AS, Lai CL, Chan TK, Todd D, Chiu EK. Hepatitis B infection in patients with lymphomas. Hematol Oncol 1990;8:261-270.
  • 13
    Sampedro B, Cabezas J, Menendez S, Ferrandiz JR, Hernandez C, Crespo J. Use of the computer physician order entry (CPOE) system to reduce the risk of hepatitis B virus (HBV) reactivation in patients prior to starting immunosuppressive system [Abstract]. Hepatology 2012;56(Suppl):641A.
  • 14
    García-Bengoechea M, Crespo J, Gea F, Zozaya JM, Pons JA, Simón MA, Gómez R, et al. Pre-immunosuppressant hepatitis B virus screening practices among various medical specialties (HEBRA Project): results of a survey from 19 Spanish hospitals [Abstract]. Hepatology 2012;56(Suppl):635A.
  • 15
    Eslami S, de Keizer NF, Abu-Hanna A. The impact of computerized physician medication order entry in hospitalized patients—a systematic review. Int J Med Inform 2008;77:365-376.
  • 16
    Ammenwerth E, Schnell-Inderst P, Machan C, Siebert U. The effect of electronic prescribing on medication errors and adverse drug events: a systematic review. J Am Med Inform Assoc 2008;15:585-580.
  • 17
    Zaal RJ, Jansen MM, Duisenberg-van Essenberg M, Tijssen CC, Roukema JA, van den Bemt PM. Identification of drug-related problems by a clinical pharmacist in addition to computerized alerts. Int J Clin Pharm 2013;35:753-762.
  • 18
    Liu CY, Chandrasekar PH, Masood A, Schiffer CA. Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation. J Oncol Pharm Pract 2013;19:18-23.
  • 19
    Aarts J, Koppel R. Implementation of computerized physician order entry in seven countries. Health Aff (Millwood) 2009;28:404-414.
  • 20
    Lee R, Vu K, Bell CM, Hicks LK. Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement. Curr Oncol 2010;17:32-38
  • 21
    Hwang JP, Fisch MJ, Zhang H, Kallen MA, Routbort MJ, Lal LS, et al. Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract 2012;8:e32-39.
  • 22
    Mendez-Navarro J, Corey KE, Zheng H, Barlow LL, Jang JY, Lin W, et al. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 2011;31:330-339.
  • 23
    Wang Y, Luo XM, Yang D, Zhang J, Zhuo HY, Jiang Y. Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study. World J Gastroenterol 2013;19:923-930.
  • 24
    Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, Lopez-Roses L, Brito-Zeron P, Perez-de-Lis M, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine 2011;90:359-371.
  • 25
    Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2013;31:118-121.
  • 26
    Park SH, Yang SK, Lim YS, Shim JH, Yang DH, Jung KW, et al. Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases. Inflamm Bowel Dis 2012;18:2004-2010.
  • 27
    Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 1996;78:2210-2215.
  • 28
    Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997;8:S107-109.
  • 29
    Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
  • 30
    Umemura T, Tanaka E, Kiyosawa K, Kumada H,Japan de novo Hepatitis BRG. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 2008;47:e52-56.
  • 31
    Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-611.
  • 32
    Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011;22:1170-1180.
  • 33
    Tsutsumi Y, Ogasawara R, Kamihara Y, Ito S, Yamamoto Y, Tanaka J, et al. Rituximab administration and reactivation of HBV. Hepat Res Treat 2010;2010:182067.
  • 34
    Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood. 2003;102:1930.
  • 35
    Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59-68.
  • 36
    Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 2012;91:1007-1012.
  • 37
    Seto W-K CT, Hwang Y, Choi O, Wong D, Fung J, Lie A, Lai C, et al. Interim analysis of hepatitis B reactivation in patients with prior HBV exposure undergoing rituximab-containing chemotherapy: a prospective study [Abstract]. Hepatology 2013;58(Suppl):224A.
  • 38
    European Center for Disease Prevention and Control. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm: ECDC. 2010.
  • 39
    Alvarez-Suarez B, de la Revilla-Negro J, Ruiz-Antoran B, Calleja-Panero JL. Hepatitis B reactivation and current clinical impact. Rev Esp Enferm Dig 2010;102:542-552.
  • 40
    Kusumoto S, Tanaka Y, Ueda R, Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 2011;46:9-16.
  • 41
    Droz N, Gilardin L, Cacoub P, Berenbaum F, Wendling D, Godeau B, et al. Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. Arthritis Care Res (Hoboken) 2013;65:1504-1514.
  • 42
    Day FL, Karnon J, Rischin D. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncology 2011;29:3270-3277.
  • 43
    Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK, et al. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 2012;30:3167-3173.